Phase II study of rapid-scheduled etoposide in paediatric soft tissue sarcomas

Phillips, MB, Flamant, F, Sommeletolive, D and Pinkerton, CR (1995) Phase II study of rapid-scheduled etoposide in paediatric soft tissue sarcomas. European Journal of Cancer, 31 5: 782-784. doi:10.1016/0959-8049(95)00092-W


Author Phillips, MB
Flamant, F
Sommeletolive, D
Pinkerton, CR
Title Phase II study of rapid-scheduled etoposide in paediatric soft tissue sarcomas
Journal name European Journal of Cancer   Check publisher's open access policy
ISSN 0959-8049
Publication date 1995-01-01
Sub-type Article (original research)
DOI 10.1016/0959-8049(95)00092-W
Volume 31
Issue 5
Start page 782
End page 784
Total pages 3
Language eng
Subject 1306 Cancer Research
2730 Oncology
2720 Hematology
Abstract Twenty three patients with paediatric soft tissue sarcomas who had relapsed or refractory disease were treated with a rapid schedule of intravenous etoposide (100 mg/m2 daily on three consecutive days, weekly over 3 weeks). The regimen was well tolerated with predictable myelotoxicity. In 19 patients with rhabdomyosarcoma, there was a response rate of 42%. This appears to be better than previously reported with conventional three weekly schedules. These data indicate that for rhabdomyosarcoma, as for some other tumours, a divided dose regimen may be the optimal schedule and is worthy of further evaluation.
Keyword childhood tumours
dose intensity
etoposide
rapid-schedule
rhabdomyosarcoma
sarcoma
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: ResearcherID Downloads
Scopus Import
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 03:58:28 EST by System User